Dr. Kumar’s Take:
Many people are prescribed statins to lower cholesterol and reduce the risk of heart attacks and strokes. But do these drugs actually help people whose risk of heart disease is low? The article I am summarizing here is a review, not a trial and not a meta-analysis of its own. Dr. John Abramson pulled together the results of several separate analyses (a large meta-analysis of statin trials, the U.S. Preventive Services Task Force primary prevention review, a randomized trial of statin-induced muscle damage, and a meta-analysis of statin-induced diabetes) and judged the balance of benefit and harm in low-risk patients. His conclusion is that the benefits in that group are very small, with no mortality benefit and no reduction in serious illness overall, while muscle symptoms are at least five times more likely than any benefit.
Actionable Takeaway:
If your doctor suggests statins but your 10-year heart disease risk is under 20%, ask about lifestyle changes first. A Mediterranean diet, exercise, and not smoking are what this review recommends focusing on before cholesterol drugs in low-risk patients.
Brief Summary:
This review gathered results from several sources on adults, typically 50 to 70 years old, at varying cardiovascular risk but primarily without pre-existing cardiovascular disease. Most of those studies enrolled patients with some elevation in blood cholesterol. The review looked at both benefits and harms.
Findings:
✔ No statistically significant mortality benefit in low-risk patients.
✔ 1 in 217 patients avoided a nonfatal heart attack.
✔ 1 in 313 avoided a nonfatal stroke.
✔ 1 in 21 experienced pain from muscle damage.
✔ 1 in 204 developed diabetes.
The review questions whether the small chance of preventing a heart attack or stroke outweighs the chance of harm, especially in low-risk individuals.
Study Design:
This was a review that summarized and weighed evidence from other studies, not a single trial and not an original meta-analysis. Its sources included:
- The 2012 Cholesterol Treatment Trialists meta-analysis, covering 22 trials with more than 130,000 patients, which reports results by baseline risk.
- The USPSTF review of statins for primary prevention, pooling 15 trials with more than 70,000 patients, used for nonfatal heart attack and nonfatal stroke.
- The STOMP trial of statin effects on skeletal muscle.
- A 2010 meta-analysis of 13 trials with more than 90,000 patients on statin-induced diabetes.
Efficacy end points were death, heart attack, and stroke. Harm end points were new-onset diabetes and muscle symptoms.
Results:
✔ No statistically significant mortality benefit in the two low-risk groups (below 10% and below 20% 10-year risk), separately or combined. The USPSTF pooled analysis did find that 0.4% fewer patients on a statin died (NNT = 250), but some of those trials included high-risk patients or patients who already had cardiovascular disease.
✔ Nonfatal heart attacks fell by 0.46% in absolute terms (NNT = 217). Within the trials, 30% to 40% fewer heart attacks occurred in the statin groups than the placebo groups.
✔ Nonfatal strokes fell by 0.32% (NNT = 313).
✔ No reduction in serious illness overall. The pooled figure was 1% lower on statins, and it was not statistically significant (95% CI 0.94 to 1.04).
✔ Muscle symptoms occurred in 4.8% of patients in the STOMP trial (NNH = 21), which also found commonly increased creatine kinase levels, a marker of muscle damage.
✔ Diabetes risk rose 9% in relative terms, an absolute increase of 0.098% per year, which works out to 0.49% over five years (NNH = 204).
The Controversy Around Statins in Low-Risk Patients
Statins reduce mortality, heart attacks, and strokes in high-risk patients (a 10-year cardiovascular risk of 20% or higher). Whether they should be used at lower risk is contested.
🔹 Most statin studies were industry sponsored, and the raw trial data continue to be withheld by manufacturers despite repeated requests from independent groups.
🔹 “Run-out phases” were used in most studies, removing patients who did not tolerate the drug or take it consistently, which makes reported harms look smaller.
🔹 The 4.8% muscle symptom rate is likely an underestimate. STOMP enrolled patients for six months, one-tenth of the median duration of the trials testing benefits. Only one of the 42 trials in a meta-analysis of statin-induced muscle problems prospectively asked patients about muscle symptoms.
🔹 Some analyses that found a mortality benefit included high-risk patients, which makes it hard to tell whether the benefit belongs to low-risk people at all.
🔹 The diabetes signal is inconsistent. The USPSTF found no increase in new-onset diabetes in primary prevention, though the best predictor of statin-induced diabetes is diabetes risk rather than cardiovascular risk. One large, high-quality trial found no increase. Originally unpublished results from the SPARCL trial showed an NNH for new-onset diabetes of just 38 with atorvastatin (Lipitor) 80 mg compared with placebo.
In this review’s judgment, muscle symptoms are at least five times more likely than any benefit, though they are typically reversible.
What You Should Do Instead
If your risk of heart disease is low, this review argues for focusing on lifestyle changes rather than cholesterol drugs.
✅ Eat a Mediterranean diet.
✅ Exercise regularly.
✅ Do not smoke.
For those at higher risk (a 10-year risk of 20% or more), statins reduce mortality, heart attacks, and strokes. For low-risk individuals, this review concludes the evidence does not support routine use.
Calculating Your Risk
Doctors use 10-year cardiovascular risk calculators to estimate your chance of a heart attack or stroke within the next decade.
What Is Considered Low-Risk?
This review treated a 10-year cardiovascular risk below 10% and below 20% as the two low-risk groups, and 20% or higher as high risk.
Why This Matters for Statins
- The mortality benefit of statins has been shown in high-risk groups (20% or higher 10-year risk), not in lower-risk groups.
- Below a 20% 10-year risk, the review found the existing evidence does not support routine statin use.
Find Your Risk Score
Use the official ASCVD Risk Calculator to estimate your 10-year risk:
If your risk is low, a Mediterranean diet, exercise, and not smoking are what this review would have you start with.
Frequently Asked Questions
Should I stop taking my statin?
Not on the strength of one review, and not on your own. Ask your doctor for your actual 10-year risk and discuss it. This review’s own position is that the decision should be shared by patient and physician rather than imposed by a guideline.
Are statins really that harmful?
In this review, muscle symptoms occurred in 4.8% of patients and were judged at least five times more likely than any benefit, though they are usually reversible. New diabetes worked out to 0.49% over five years. Other adverse events, although often reported, have not been well studied.
How do I know if I’m at high or low risk?
Your doctor can calculate your 10-year cardiovascular risk. If it is below 20%, this review argues for lifestyle changes first.
Are there safer alternatives to statins?
The alternatives this review names are a Mediterranean diet, exercise, and not smoking. Talk to your doctor before changing any medication.
Conclusion
This review found no significant mortality benefit from statins in low-risk patients, no reduction in serious illness overall, roughly a 1% chance of avoiding a nonfatal heart attack or stroke, a similar or greater chance of developing diabetes, and a 1 in 21 chance of muscle damage. Its author categorized statins for low-risk patients as not recommended, and argued that reported benefits likely represent a best case while harms are likely underestimated.
Before starting or stopping any medication, speak with your doctor about your true risk and the best strategy for your health.
